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A novel method of preparing hybridomas producing mouse monoclonal antibodies was
established, called “the mouse iliac lymph node method”. Lymphocytes from enlarged iliac
lymph nodes from mice injected intramuscularly at the tail base with an emulsion of antigen
and Freund’s adjuvant were used for cell fusion. For the most part, lymph node lymphocytes
from two mice were used for a single cell fusion attempt. Ovalbumin was used as the antigen
and the results of fusion were compared with the results of a previous report (Cell Struct.
Funct. 20; 151–156, 1995). Approximately 100 positive wells producing antibody of interest
were identified using this method. By comparison, approximately 10 positive wells were iden-
tified using the more conventional mouse spleen method after three immunization injections.
The relative proportions of hybridomas producing IgM, IgG1, IgG2a, IgG2b, and IgG3, fol-
lowing fusion using iliac lymph node lymphocytes obtained 14 days after injection were
14.0%, 78.7%, 3.2%, 3.5% and 0.5%, respectively. This method demonstrated the following
advantages: (1) a single injection of the antigen emulsion was sufficient, (2) the lymph nodes
were ready for use 14 days after injection, and (3) a high yield of positive hybridomas was
obtained.
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I. Introduction
Since monoclonal antibodies were first produced in
mice 30 years ago [7], mouse monoclonal antibodies have
been produced using sensitized lymphocytes from the mouse
spleen. The use of mouse lymph node lymphocytes for the
production of mouse monoclonal antibodies has not been
extensively examined [2, 3, 8], however they can be used
for cell fusion. The only limiting factor to date has been
the small number of lymph node lymphocytes able to be
obtained from a mouse, which is insufficient for cell fusion
[2, 9].
In 1995, we described a novel method, known as the
rat lymph node method, in which medial iliac lymph node
lymphocytes from rats immunized with an antigen emul-
sion via the hind footpads are used as fusion partners for cell
fusion [5]. This produces approximately 10-fold the number
of specific antibody-producing hybridomas than the more
conventional method using mouse or rat splenic lympho-
cytes [5]. However, this method cannot be used in mice,
since injection of an antigen emulsion into the hind foot-
pads of mice does not result in sufficient enlargement of
draining lymph nodes, such as the popliteal, inguinal, and
iliac lymph nodes, to enable cell fusion.
Through trial and error, we discovered that intramus-
cular injection of the tail base with an antigen emulsion
enlarges mouse iliac lymph nodes very effectively, and
that lymph node lymphocytes from two immunized mice
are sufficient for a single cell fusion attempt. The mouse
method using lymphocytes from enlarged lymph nodes
demonstrated similar characteristics to the rat lymph node
method [5], with the following advantages: (1) one injection
of antigen emulsion was sufficient, (2) the lymph nodes
were ready for use two weeks after injection, and (3) a high
yield of positive hybridomas was obtained.
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II. Materials and Methods
Animal immunization
Chicken ovalbumin (Grade VII, Sigma, St. Louis, MO,
U.S.A.) and Freund’s complete adjuvant (Difco Labora-
tories, Detroit, IL, U.S.A.) were used for making antigen
emulsion. Freund’s complete adjuvant (0.6 ml) and 1.5
mg/ml chicken ovalbumin solution (0.3 ml) were emulsified
in two 1-ml Luer-lock glass syringes with a double-ended
locking needle connector. After emulsification was com-
pleted, one of the glass syringes containing the emulsion was
disconnected from the locking connector and a 27G3/4”
needle attached.
Eight-week-old female mice were used. BALB/
cAnNCrlCrlj mice (BALB/c) were purchased from Charles
River Laboratories Japan, Inc., Yokohama, while C3H/
HeNJcl mice (C3H/He), and closed colony Jcl: ICR mice
(ICR), were purchased from Clea Japan, Inc., Tokyo. Mice
were anesthetized and injected intramuscularly at the right
and left tail base with an emulsion (0.1 ml in total) contain-
ing 50 g chicken ovalbumin and Freund’s complete adju-
vant. Nine BALB/c mice were injected subcutaneously at
the tail base with the same amount of antigen emulsion.
The mice were kept in polycarbonate plastic cages con-
taining wood shavings for bedding. All animal experiments
were conducted in accordance with the Guidelines for Labo-
ratory Animal Experiments of the Shigei Medical Research
Institute.
Cell fusion
A mouse myeloma cell line, SP2/0-Ag14 [10], was
used for cell fusion. Mice were sacrificed 11, 14, 21, and 28
days after injection. Iliac lymph nodes were collected and
lymph node lymphocytes from 2 mice were pooled and used
for each cell fusion attempt. Cell number was determined
using a blood corpuscle counting chamber after lymph nodes
were passed through a 200-mesh stainless steel wire mesh.
Cell fusion was performed according to the method of
Kishiro  et al. [5], after which the cells were cultured in
four 96-well plates. On days 9 and 10 after cell fusion, cul-
ture supernatant was collected and assayed by solid-phase
enzyme-linked immunosorbent assay (ELISA).
Serum antibody titers and screening assay
Mouse serum was collected at sacrifice and serum anti-
body titers against ovalbumin were determined by ELISA
using the 2-fold dilution method [5].
Supernatant collected from the 96-well culture plates
was screened for the production of anti-ovalbumin anti-
bodies using ELISA, according to the method of Kishiro
et al. [5]. Rabbit antibodies to mouse immunoglobulins
(Dako A/S, Glostrup, Denmark), and sheep antibodies to
mouse IgM, IgG1, IgG2a, IgG2b, and IgG3 (Nordic Immuno-
logical Laboratories, Tilburg, Netherlands), were used as
peroxidase-conjugated secondary antibodies. Positive wells
were defined as wells that showed an absorbance of 0.3
units or higher.
Statistical analysis
Statistical analyses were performed with the StatView
program (Abacus Concepts, Berkeley, CA, USA) using
Student’s t-test. P values of less than 0.05 were considered
statistically significant.
III. Results
Enlarged mouse iliac lymph nodes
Intramuscular tail base injection (Fig. 1) of an emulsion
containing antigen and adjuvant induced hypertrophy of the
iliac lymph nodes in the mice (Fig. 2a). Enlargement of both
the right and left iliac nodes usually occurred, and a range
of sizes was observed. Often, two iliac lymph nodes were
present on either side of the caudal vena cava; however,
sometimes three lymph nodes were present. They were
spherical in shape and usually approximately 2 to 4 mm
wide, 3 to 5 mm long, and contained anywhere from 1107
to 2107 cells per mouse after immunization (Fig. 2b). The
injected antigen emulsion was always found in the muscles
of the tail base, and often found in the sacral lymph nodes
and within cysts in the peritoneal cavity.
To find and collect the iliac lymph nodes from age-
matched normal mice was more difficult than to find and
collect the enlarged iliac lymph nodes of immunized mice,
due to the small size of the nodes and their being buried
under the retroperitoneal membrane in the normal mice. The
iliac lymph nodes from the normal mice were spherical in
shape, usually about 1 mm wide, 1 to 2 mm long, and con-
tained anywhere from 1106 to 2106 cells per mouse (Fig.
2c).
Nine mice injected with antigen emulsion subcutane-
ously at the tail base were sacrificed 14 days after the injec-
tion to confirm the injection site effect. The inguinal lymph
nodes were enlarged in all mice; however, the iliac lymph
nodes remained normal in size in 7 of the 9 mice. In the
2 mice with the enlarged iliac lymph nodes, a portion of the
emulsion was present in the muscle at the injection site.
Fig. 1. Intramuscular injection of antigen emulsion into the tail base
of a mouse.Iliac Lymph Node Cells as Fusion Partners 91
Serum antibody titers
The serum antibody titers of mice sacrificed 11, 14, 21,
and 28 days after injection were measured (Table 1).
Although large individual variations were observed, the
median value at day 14 remained low but increased rapidly
thereafter, reaching a plateau around day 21.
Culture of hybridoma cells
After cell fusion, the cells were cultured in four 96-well
culture plates. Hybridoma colonies were confirmed 4 days
after cell fusion. There were several well-grown colonies in
each well. Positive wells were detected by ELISA of the
culture supernatant at least 9 days after cell fusion. Figure
3 shows a histogram of the results of ELISA screening
to detect positive wells following cell fusion using iliac
lymph node lymphocytes from mice sacrificed 14 days after
immunization with the antigen emulsion.
Timing of fusion
The number of positive wells was examined using
lymphocytes obtained 11, 14, 21, and 28 days after injec-
tion of the antigen emulsion. Fusion was performed using
iliac lymph node lymphocytes from two injected mice. Three
independent fusion experiments were performed using
lymphocytes from each post-injection time period exam-
ined. As shown in Figure 4, a large number of positive wells
were obtained using lymphocytes 14 and 21 days after injec-
tion. Positive wells were also present using lymphocytes
obtained at 11 and 28 days, but at a third of the concentra-
tion observed using lymphocytes obtained at 14 and 21 days.
IgM and IgG subclasses
The production of IgM and IgG antibodies was identi-
Fig. 2. a: Enlarged iliac lymph nodes (arrows) from a BALB/c
mouse injected with antigen emulsion. C, colon; L, liver; S, Spleen;
U, uterus; CV, caudal vena cava. Bar5 mm. A small portion of the
antigen emulsion was found in the sacral lymph node. b: Enlarged
iliac lymph nodes in culture medium from two BALB/c mice 14
days after injection of the antigen emulsion. The scale of the graph
paper is 1 mm. c: Normal iliac lymph nodes from an age-matched
BALB/c mouse.
Table 1. Titer of antibodies in the serum of immunized mice
Day 11 Day 14 Day 21 Day 28
Number of mice 8 8 8 8
Minimum titer 40 100 3200 1600
Maximum titer 640 3200 25600 51200
Median titer 320 1600 9600 12800
Serum titer was defined as the reciprocal of the highest dilution
giving an absorbance reading 0.1 unit greater than the control using
ELISA.
Fig. 3. Histogram of screening results of supernatant for primary
hybridomas by ELISA nine days after cell fusion using iliac lymph
node lymphocytes from two mice immunized 14 days before. Wells
with absorbance of 0.3 units or greater were defined as positive
wells, and 103 positive wells were found.Sado et al. 92
fied after mouse lymph node lymphocyte fusion (Table 2).
IgG1 was the main subclass observed using lympho-
cytes obtained 11, 14, 21 and 28 days after injection. This
was followed by IgM, which was found in approximately
14% of positive wells at day 14, after which levels decreased
with time, being present in only 3.4% of positive wells 28
days after fusion (Table 2). In contrast to the trends demon-
strated by IgM and IgG1, the relative proportions of IgG2a
and IgG2b varied from one fusion experiment to another.
Only 4.0% to 6.7% of positive wells produced these sub-
classes. Only two wells producing IgG3 subclass antibodies
were observed in a total of 12 fusion experiments in the
present study.
Iliac lymph nodes of C3H/He and ICR mice
In addition to BALB/c mice, C3H/He and ICR mice
were injected with the antigen emulsion. As expected, the
iliac lymph nodes from these strains of mice enlarged fol-
lowing antigen injection, although more variation in lymph
node size on the right and left was observed than in the
BALB/c mice.
Two attempts at cell fusion were made for each strain
using iliac lymph node lymphocytes obtained 16 days after
immunization. Forty-four and 111 positive wells were found
in C3H/He mice, and 92 and 103 in ICR mice, on each
attempt. Thus, this method can be used for other strains, in
addition to BALB/c mice.
IV. Discussion
The number of positive wells obtained using the
present method was 75 to 130 per cell fusion attempt when
lymph node lymphocytes were used 14 to 21 days after
injection. These numbers are much higher than those
obtained in a previous study [5] using the mouse spleen
method, which generated 9 to 11 positive wells per cell
fusion attempt. In addition, the mouse spleen method
requires three immunizations over a four-week immuniza-
tion period. These results clearly indicate that the use of
Fig. 4. Timing of cell fusion using the mouse iliac lymph node
method. Data points indicate the results of independent experi-
ments, and the line indicates the mean of all the experiments. The
differences in the means between days 11 and 14, days 11 and 21,
days 14 and 28, and days 21 and 28 were statistically significant.
Table 2. Relative proportions of IgM and IgG produced by hybridomas using the mouse iliac lymph node method
IgM IgG1 IgG2a IgG2b IgG3 Total
day 11-Exp. 1 11 27 0 1 0 39
day 11-Exp. 2 9 31 0 0 0 40
day 11-Exp. 3 8 32 0 0 0 40
Total 28 90 0 1 0 119
(23.5%) (75.6%) (0.0%) (0.8%) (0.0%) (100%)
day 14-Exp. 1 12 92 0 2 0 106
day 14-Exp. 2 20 91 11 4 1 127
day 14-Exp. 3 20 109 1 7 1 138
Total 52 292 12 13 2 371
(14.0%) (78.7%) (3.2%) (3.5%) (0.5%) (100%)
day 21-Exp. 1 16 101 7 4 0 128
day 21-Exp. 2 9 64 2 0 0 75
day 21-Exp. 3 6 118 0 0 0 124
Total 31 283 9 4 0 327
(9.5%) (86.5%) (2.8%) (1.2%) (0.0%) (100%)
day 28-Exp. 1 1 18 3 1 0 23
day 28-Exp. 2 3 27 13 12 0 55
day 28-Exp. 3 0 38 1 0 0 39
Total 4 83 17 13 0 117
(3.4%) (70.9%) (14.5%) (11.1%) (0.0%) (100%)Iliac Lymph Node Cells as Fusion Partners 93
enlarged iliac lymph node lymphocytes from mice injected
intramuscularly with an antigen emulsion via tail base is an
excellent method by which to prepare hybridomas producing
mouse monoclonal antibodies. We named this method the
“mouse iliac lymph node method” or more simply, the
“mouse lymph node method”. It has several advantages.
Specifically, only one antigen injection is required and
lymph nodes can be used from approximately two weeks
after injection. Lymph node lymphocytes from two mice are
sufficient for a single fusion attempt, and a high yield of
positive wells is obtained. This method saves time, effort,
antigen requirements, expense, and has a better chance of
success.
It has been 30 years since the first report by Köhler and
Milstein of monoclonal antibodies appeared in Nature [7].
However, the present study is the first to describe mono-
clonal antibody production using a mouse iliac lymph node
method. The major reason for this delay has been the small
size of mouse lymph nodes, which necessitates 5 or more
mice to be injected for immunization for a single cell fusion
[2, 8, 9]. Another reason is that high antibody titers in serum
have been thought to indicate the potential for success of cell
fusion, and high titers are achieved with the mouse spleen
method. This generally requires two or three booster injec-
tions, requiring at least four weeks from the time of initial
injection. This long period of immunization might in fact
reduce the number of positive wells obtained and make it
difficult to achieve the success of the present mouse lymph
node method.
A particular stage of B cell differentiation is thought to
be most suitable for cell fusion in order to produce antibody-
secreting hybridomas [1, 4, 12]. In the conventional mouse
spleen method [12], the last booster injection is usually
made intravenously with antigen in saline 3 or 4 days before
cell fusion to induce the splenic lymphocytes into a suitable
stage for cell fusion [12]. Using the present mouse iliac
lymph node method, the greatest number of positive wells
was observed using lymphocytes obtained 14 to 21 days
after injection, and decreased numbers were observed using
lymphocytes obtained 28 days after injection. Since the
iliac lymph nodes were similar in size 14 and 28 days after
injection, and since similar numbers of hybridomas were
observed in each well from one fusion attempt to the next,
the observed decrease at day 28 in the proportion of positive
wells may have been due to a shift of B cells into an unsuit-
able stage.
Hybridomas produced using the mouse lymph node
method primarily produced IgG1 antibodies (approximately
80% of total antibody production), but IgM, IgG2a and
IgG2b antibodies were also obtained. IgM was easily
obtained when mouse lymph nodes were used two weeks
after injection. Individual mouse differences were observed
with regard to the production of IgG2a and IgG2b; however,
these subclasses were obtained after several attempts at cell
fusion.
Mirza et al. [8] reported in 1987 that immunization by
injection of antigen into the hind footpads of mice with sub-
sequent fusion of lymphocytes from popliteal and inguinal
lymph nodes produced more antibody-secreting hybridomas
than either intradermal immunization and lymph node
lymphocyte fusion or conventional subcutaneous immuni-
zation with intraperitoneal booster injections followed by
splenic lymphocyte fusion. However, this method remains
unpopular since lymph node lymphocytes from five mice
are required for a single fusion attempt. Moreover, lymph
node enlargement is less successful than with the current
method. We tried to immunize mice in the same way as
Mirza et al. [8] but found it impossible to inject 50 l of
antigen emulsion into a footpad without leakage. At most,
we were able to inject 15 l of the emulsion. Of note, the
injection site became less obvious several days after injec-
tion (unpublished data). In contrast, intramuscular tail base
injection of 50 l of emulsion was easy, and the injected
emulsion was still evident in the intramuscular space 28
days after injection.
Davis et al. [3] produced monoclonal antibodies fol-
lowing a single fusion attempt using a mixture of lympho-
cytes from inguinal and iliac lymph nodes from 10 mice.
Although they used iliac lymph node lymphocytes as the
source of B lymphocytes for the first time, their method is
clearly different from the present mouse lymph node
method. They injected the mice subcutaneously, not intra-
muscularly, at the tail base four times at two-week inter-
vals, and used both inguinal and iliac lymph nodes. Judging
from the results of subcutaneous injection in the present
study, subcutaneous injection at the tail base of a mouse
induces hypertrophy of inguinal lymph nodes, although
enlargement of both inguinal and iliac lymph nodes occa-
sionally occurs. The main target lymph nodes in the Davis
et al. study were thought to be the inguinal lymph nodes.
They established 43 antibody clones; however, these
results were similar to those obtained following three fusion
attempts using splenic lymphocytes from mice after adminis-
tration of a similar schedule of intraperitoneal injections [3].
As such, they did not feel there was any great advantage
to using lymph node lymphocytes as the source of B
lymphocytes.
The effect of booster injections was not examined in
the present study, because booster injections given three or
four days prior to sacrifice did not influence the number of
positive wells obtained using the rat lymph node method in
a previous study [5]. Typically, booster injections are given
at least one week after initial immunization, which would
lengthen the immunization period required for this experi-
ment and increase the amount of antigen required. The anti-
gen saved could then be used to immunize more mice.
We have previously reported on a rat lymph node
method [5]. This method uses lymphocytes obtained from
enlarged medial iliac lymph nodes following hind footpad
immunization for cell fusion. Intramuscular tail base injec-
tion of antigen into rats to obtain lymphocytes for cell fusion
was also examined in the present study, and tail base injec-
tion was observed to produce enlarged rat medial iliac
lymph nodes, from which lymphocytes for cell fusion wereSado et al. 94
obtained and a number of hybridomas detected by ELISA
(unpublished data). Therefore, the present study is the first
report indicating that the iliac lymph node method is also
useful in rats. The tail base is a more humane site for immu-
nization than the hind footpads. Thus, researchers should use
the tail base for immunization when using the rat lymph
node method to achieve monoclonal antibody production
using lymphocytes from enlarged medial iliac lymph nodes.
Given the immunotolerance of rats to various rat anti-
gens, monoclonal mouse antibodies have an important role
in research. Rabbit monoclonal antibodies are commercially
available from Knight’s group [11]; however, a number of
researchers are interested in producing their own rodent
monoclonal antibodies. Although this data has not been pub-
lished, we were able to produce antibodies to a rat antigen
using the mouse lymph node method. We produced more
than 30 clones of antibodies against rat renal basement
membrane collagen, otherwise known as type IV collagen
[6]. For this we used a soluble fraction purified from rat sol-
ubilized renal basement membrane as the antigen [6]. We
established approximately 10 clones each of IgG1, IgG2a,
and IgG2b, all of which were strongly reactive with native
rat renal basement membrane, as demonstrated by indirect
immunofluorescence. This required four cell fusion attempts
since only approximately 10% of the positive wells con-
tained IgG2a and IgG2b antibodies, while the rest contained
IgG1. This clearly indicates that the mouse lymph node
method is a reliable technique.
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